| Bioactivity | Simaravibart (MAD-0004J08) is an IgG1κ antibody targeting the SARS-CoV2 spike (S) glycoprotein receptor binding domain[1]. |
| Target | SARS-CoV2 |
| Name | Simaravibart |
| Storage | Please store the product under the recommended conditions in the Certificate of Analysis. |
| Reference | [1]. Lim SP. Targeting SARS-CoV-2 and host cell receptor interactions. Antiviral Res. 2023 Feb;210:105514. |